Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

3rd Annual Stability Testing Conference

Next-Gen Sequencing Trends 2009

Competitor Analysis: c-MET/HGF Inhibitors

The Japanese Pharmaceutical Market 2008-2023

New Products

Japanese Pharmaceutical Market 2009-2024

3rd Annual Lyophilisation Conference

The Global Bioinformatics Market: Market size, forecasts and company profiles

Pharmaceutical Mergers and Acquisitions (PH133)

Pharmaceutical Speaker Programs (PH134) Measuring ROI and Communicating Value

Strategic Clinical Sourcing (PH125)) Managing Costs and CROs

The Global Analgesics Market 2009-2024

Competitor Analysis: Coagulation Factors

Competitor Analysis: PDGF-R Agonists and Antagonists

World Market for Addiction Disorders, 2009-2016

BioPortfolio | Pharmalicensing Reports | The China Pharmaceutical Market A Strategic Opportunity Analysis 2007

The China Pharmaceutical Market A Strategic Opportunity Analysis

China has become an attractive destination for R&D as new opportunities have emerged following its WTO (World Trade Organization) accession. Development has accelerated both industrially and scientifically, and today the Chinese pharmaceutical market is worth around $US12 billion.

Factors fuelling the developmental growth and attracting foreign investors to the area include low labor costs, high quality clinical data and an abundance of R&D collaborative opportunities and facilities.

Global biotechnology within China has also undergone significant growth, promising enormous potential for new companies. Biotechnology companies in the country have already grown quicker than pharmaceutical companies.

The report discusses the whole of the Chinese pharmaceutical market, taking readers through the history and current state of the healthcare system through to the regulations governing the country and its growing R&D capabilities. Detailing the driving forces behind the pharma market and including a full breakdown of the biopharma opportunities, including the contacts of active Chinese companies, the report is an essential resource to understand and access this lucrative market.

Reasons to purchase this report:

Identify key partners

Assess the current market opportunity

Learn how newly implemented government changes have altered the face of the industry

Understand the organization and success of clinical trials in China

Create strategies for profitable market access into China

The Chinese government also plays an instrumental role in the pharmaceutical development of China. The introduction of WTO guidelines and protection for intellectual property rights has caused a shift in the company structures of China, forcing some to close business or enter into new collaborations.

Ideally suited for individuals wishing to introduce their companies into this emerging market or review the opportunities available, this report provides a perfect resource to identify the current pattern of the market and understand the regulations that operate within the country.

100 pages

Published Jan 2007

PDF Format
Table of Contents
Price: $1,200.00 / €802.80

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions